Tiziana Life Sciences, Ltd. (TLSA), a biotechnology company focused on immunomodulation therapies, announced that CEO Ivor Elrifi purchased 193,848 shares of company stock at $1.65 per share in the open market.
The company's lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to stimulate T regulatory cells. In an Expanded Access Program, 10 patients with non-active secondary progressive multiple sclerosis (na-SPMS) showed either improvement or disease stability within six months.
Foralumab is currently under evaluation in a Phase 2a randomized, double-blind, placebo-controlled trial for non-active SPMS. It remains the only fully human anti-CD3 monoclonal antibody in clinical development and represents a novel approach to treating neuroinflammatory and neurodegenerative diseases.
TLSA currently trades at $1.8101 or 11.6504% higher on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.